Vaccines 2016: Big Bets for Global Threats

Friday, March 4, 2016

Another biotech firm with a California startup address that thinks it can leverage its expertise is Redwood City-headquartered PaxVax. “Along with many others, PaxVax is now in the early stages for developing a Zika vaccine,” according to CEO Nima Farzan. 

The company has worked on dengue and has proprietary technology targeting that virus, which Farzan thinks could also be applied to Zika. The company hopes to take its early findings into animal tests soon, he stated. PaxVax’s business model emphasizes the pursuit of socially responsible strategies to address unmet medical need while finding a profit by serving the affluent  traveler’s vaccine market. This will give it both the tools and resources to positively  impact the spread of infectious diseases of the developing world.